期刊文献+

不同类型冠心病患者血清基质金属蛋白酶9含量及意义 被引量:2

Changes and roles of serum matrix metalloproteinases-9 in patients of coronary heart disease
下载PDF
导出
摘要 目的观察冠心病患者血清基质金属蛋白酶9含量,探讨血清基质金属蛋白酶9在冠心病发病及病程进展中的意义。方法随机选取经冠脉造影证实的冠心病患者45例作为研究组,根据病情的严重程度分为3个亚组:稳定型心绞痛组、不稳定型心绞痛组和心肌梗死组各15例,又根据冠状动脉造影所示的冠状动脉病变程度分为3个亚组:单支病变组12例、双支病变组19例、三支或左主干病变组14例。对照组选择15例同期健康体检的健康人。血清基质金属蛋白酶9检测选用分光光度法检测。将冠心病患者组的检测结果与对照组结果进行统计学处理。结果①冠心病稳定型心绞痛、不稳定型心绞痛组和心肌梗死组3个亚组的血清基质金属蛋白酶9的浓度分别为(356.8±156.2)ng/ml、(620.3±173.1)ng/ml、(856.9±260.8)ng/ml,各组均高于正常对照组(124.2±37.6)ng/ml,且各组间均有统计学差异(P<0.05)。②单支病变组、双支病变组、三支或左主干病变组三个亚组的血清基质金属蛋白酶9浓度分别为(315.2±98.6)ng/ml、(478.8±152.2)ng/ml、(603.3±283.1)ng/ml,各组间均有统计学差异(P<0.01)。结论冠心病患者组血清基质金属蛋白酶9水平与健康人对比相对较低,并与病情严重程度和冠状动脉病变的严重程度相关。提示内源性血清基质金属蛋白酶9的增加参与了冠心病发生发展的过程。 Objective To determin levels of serum matrix metalloproteinases-9(MMP-9) in coronary heart disease patients and to investigate the roles of MMP-9 in the pathogenesis of coronary heart disease. Methods 45 coronary heart disease patients were randomly enrolled as study group and assigned into 3 subgroups according to stable angina patients and unstableangina and myocardial infarction. Control group concluded 15 health persons. And other 3 subgroup acording to the degree of pathological changes of coronary artery, as one branch changes (12cases) and two branch changes (19cases) and three branch or left main branch changes (14cases). Serum matrix metalloproteinases-9 were determined by spectrometer. Data were processed by statistical methods which conclude T-test, F-test. Results ① The levels of MMP-9 in coronary heart disease were significantly increased than that of normal controls (356.8±156.2)ng/ml, (620.3±173.1)ng/ml, (856.9±260.8) ng/ml respectively. There were significant differences between any two of the groups (P〈0.01). ②The concentrations of MMP-9 in the other 3 subgroups were (315.2±98.6)ng/ml, (478.8± 152.2)ng/ml, (603.3±283.1)ng/ml, respectively. There were significant differences between any two of the groups(P〈0.01). Conclusion The concentrations of serum matrix metalloproteinases-9 were higher in coronary heart disease patients, and there were positive correlation between MMP-9 level and coronary heart disease levels. The study indicate that the short of MMP-9 take part in the pathogenesis of coronary heart disease.
作者 王开侠
出处 《中国现代医药杂志》 2008年第9期41-43,共3页 Modern Medicine Journal of China
关键词 冠心病 血清基质金属蛋白酶9 患者 临床分析 Coronary heart disease Serum matrix metalloproteinases-9
  • 相关文献

参考文献2

  • 1[1]Funayama H,Ishikawa SE,Kubo N,et al.Inereases in interleukin6 and matrix metal loproteinase-9 in the infaret-mimed coronary artery of actuc myocardial infaction[J].Cire J,2004,68(5):451-454
  • 2[2]Wu CY.Hsieh HL,Jou MJ,et al.Imolvement of p42/p44 MAPK,p38 MAPK,JNK and nuclear factor-kappa B in interleukin-1 beta-induced Matrix metal loproteinase-9 expression in rat brain astrocytes[J].J Neurochem,2004,90(6):1477-1488

同被引文献23

  • 1吕艳,柳茵,郭帅.基质金属蛋白酶-9、颈动脉内中膜厚度与冠心病关系的研究[J].青海医学院学报,2006,27(2):86-89. 被引量:3
  • 2PACKARD C J,O′REILLY D S,CASLAKE M J,et al.Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease West of Scotland Coronary Prevention Study Group[J].N Engl J Med,2000,343(16):1148-1155.
  • 3SUDHIR K.Lipoprotein-associated phospholipase A2,vascular inflammation and cardiovascular risk prediction[J].Vasc Health Risk Manag,2006,2(2):153-156.
  • 4B RILAKIS E S,MCCONNELL J P,LENNON R J,et al.Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk factors,angio -graphic coronary artery disease,and major adverse events at follow-up[J].Eur Heart J,2005,26(2):137-144.
  • 5CORSETTI J P,RAINWATER D L,MOSS A J,et al.High lipoprotein-associated phospholipase A2 is a risk factor for recurrent coronary events in postinfarction patients[J].Clin Chem,2006,52(7):1331-1338.
  • 6CORSETTI J P,RAINWATER D L,MOSS A J,et al.High Lipoprotein-Associated Phospholipase A2 Is a Risk Factor for Recurrent Coronary Events in Postinfarction Patients[J].Clin Chemistry,2006,52(7):1331-1338.
  • 7MERTENS A,HOLVOET P.Oxidized LDL and HDL:antagonists in atherothrombosis[J].FASEB J,2001,15(12):2073-2084.
  • 8OEI H H,VAN DER MEER I M,HOFMAN A,et al.Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke:the rotterdam study[J].Circulation,2005,111(5):570-575.
  • 9BALLANTYNE C M,HOOGEVEEN R C,BANG H,et al.Lipoprotein-associated phospholipase A2,high-sensitivity C-reactive protein,and risk for incident coronary heart disease in middle-aged men and women in the atherosclerosis risk in communities (ARIC) study[J].Circulation,2004,109(7):837-842.
  • 10NICCOLI G, BURZOTYA F, GALIUTO L, et al. Myocardial no-reflow in humans [J]. Am Coll Cardiol, 2009, 54 (4) : 281-292.

引证文献2

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部